Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Crabtree & Hidalgo’s relationship with Bristol is very compelling.
We will find out soon
WE CAN SEE THE FINISH LINE HERE PEOPLE! —ETA 1 YEAR— MAJOR GAINS FDA approval, NASDAQ up listing and more.
///// curt /////
“...I emailed Gerry (Dr.Gerald Crabtree) and kw (CEO Kenneth Waggoner) yesterday... and about 3 months ago he said it would take about 8 months to complete... to get more capital to be able to finish the required testing... there will be a reverse split and then they will uplist to nasdaq.”
“...it looks like a 20 to 1 split it’s the right way to go... that’s why they got the accounting firm (ONE YEAR) the board members are the same ones they already have (ONE YEAR)”
“...just believe and be patient this will go and lengthen many lives good luck to the believers”
PMCB’s Cell-in-a-Box technology and the positive shift in the medical landscape for such treatment presents an extraordinarily high value following FDA approval and upon up listing to NASDAQ (this is happening within or at and around a years time from today) Nano cellular encapsulation treatments are currently and by far thee best option against tumors. The trendy and compatible focus on gene editing and the adaptive immune treatments are so far unable to handle the hostile environment of a cancerous tumor.
“...there were 25% more deals worth over $1 billion up front. Many of them underscored the continued popularity of targeted oncology, immunology and rare-disease assets, as well as an increasing confidence in experimental therapy platform technologies using oligonucleotide, gene- or cell-therapy modalities.”
PMCB likely up-listing (NASDAQ)
1. To elect seven directors as nominated by the Board of Directors of PharmaCyte (“Board”), each to serve a one-year term;
-PMCB is doubling the number of Directors. The 7 new directors would serve a 1 year term. Interesting.
2. To approve a Certificate of Amendment to PharmaCyte’s Articles of Incorporation to increase the number of our authorized shares of common stock;
-Allowing them to raise money opportunistically and take advantage of strong capital markets or simply strong interest in their stock should be a good thing.
3. To approve PharmaCyte’s 2021 Equity Incentive Plan; and
-tbd
4. To ratify PharmaCyte’s appointment of Armanino LLP as PharmaCyte’s independent registered public accounting firm for the fiscal year ending April 30, 2022.
-The announcement will be earlier but I bet in or around a year from now the actual listing will take place. They probably need this accountant so they have one year of certified year end statements.
PREDICTION ///////////
PMCB goes public as Austrianova-
PMCB and Austrianova’s current partnership is reconfigured to reflect their current trajectory in conjunction with their mutual interests and the terms of the lender (GEM) via a SPAC merger -which may or may not include an additional bio based company- within the agreement.
PMCB’s stock price explodes following the announcement.
My current PMCB gains https://i.imgur.com/1DO10Oj.png
-no pumping or dumping here-
I will keep posting at 16,400,000
Subscription credit facilities provided by a lender (GEM) typically involve a pledge by the fund borrower (Ausrianova) and its general partner or other managing entity (PMCB) to:
•The right in and to the unfunded capital commitments of the -investors-
•The right to make capital calls and to enforce the obligations of the -investors- to contribute capital; and
•The deposit account into which -investors- are required to fund their contributions.
Lender (GEM Global Yield LLC SCS)
Fund (Austrianova IPO)
Partner or Managing Entity of Fund (PMCB)
Investors (GEM, 3rd Party, SPAC, future Aus-IPO investors)
https://www.einnews.com/pr_news/539088704/austrianova-secures-100-million-usd-investment-commitment-from-gem-as-company-seeks-to-go-public
Lol nice
1.PMCB has a 14.5% equity interest in Austrianova
2.PMCB has the rights to CIAB. Wether it remains exclusive or not after 1.5 years.
3.PMCB has an extensive 20 year patent that doesnt begin until clinical trials begin and will include further patent pending material.
4.PMCB has EVERYTHING organized following an FDA approval.
5.PMCB for 1.5 years has a -right of first refusal- currently in place. I cant imagine a deal being made without PMCBs approval.
PMCB was given the licensing right to Austrianovas cell-in-a-box technology by Austrianova. PMCB was also given a 14.5% equity “stake” in Austrianova. (PMCB provided financing, etc.) PMCB has another 1.5 years to get shit done or lose the exclusive rights to the technology. Rights to the technology remains. The 14.5% interest in Austrianova remains. MY OPINION: PMCB has EVERYTHING set up and ready to go once the FDA’s list pertaining to the clinical hold is addressed. PMCB has significant value at this stage. Austrianova has been in the thick of things with PMCB for seven years. PMCB has 14.5% equity interest in Austrianova. PMCB will retain rights to use this technology regardless if its exclusive or not. PMCB has an incredibly in depth patent established with additional patent pending material surrounding further uses of the technology. Austrianova and PMCBs interests are linked across the board. They will continue to push forward together. MY GUESS: PMCB and Austrianova bring in a third party SPAC -go public- and get this technology to clinical trial ASAP. IMO there are massive gains to be had for investors regardless of what form PMCB takes following an agreement.
There is an elephant in the room right now and if he’s friendly we are all going to make a #$%$ load of money.
PMCB is in an incredible position. They are embedded into years of progress with Austrianova. Things I see worth considering atm:
“In addition, the Term Sheet provides that the Company (PMCB) will have a 5-year right of first refusal in the event that Austrianova chooses to sell, transfer or assign at any time during such period the Cell-in-a-Box® tradename and its associated technology, intellectual property, trade secrets and know-how, which includes the right to purchase any manufacturing facility used for the Cell-in-a-Box® encapsulation process and a non-exclusive license to use the special cellulose sulphate utilized with the Cell-in-a-Box® encapsulation process..”
(August 30 2017)
Did PMCB have to agree to this GEM/Austrianova deal?
+
PMCB retains a 15% equity interest in Austrianova
——
“This Agreement with GEM helps secure funding for continued growth and development of Austrianova as we continue to expand the number of partners using our Cell-in-a-Box® and Bac-in-a-Box® technologies" stated Walter H Gunzburg, Chairman of Austrianova.”
I believe CONTINUE, EXPAND, PARTNERS and USING are keywords here. My biggest question is why and in what sense must PARTNERS be USING the technology and what other PARTNERS have previously been USING their technology.
I think defining what Gunzburg’s definition of “USING” is important in determining what will happen next.
I am convinced and I am loving it. I feel incredibly lucky. Immunotherapy is amazing but its got some serious limitations and these Big Pharma companies know that. So we are going to start seeing different combinations of chemo drugs, radiation, gene editing, and microencapsulation technology like cell-in-a-box. The timing is perfect. Not only with PMCBs current price but also because of the shift in the medical landscape and new technology that can support the additional tests that the FDA requires of PMCB. Many of which didnt exist years ago. I have read hours and hours of academic reviews and bio articles. Most of which didnt tell me much but eventually I started to get to the good #$%$ I just had to change my wording when I searched. Public awareness is low right now. Pharma is aware. Eli Lilly is definitely aware. They have already started capitalizing on similar technology which sends a big statement because it goes against how they currently profit. Now I am going to sit back and relax. Their is only profit to be made here. The question is when and how much.
(Cell-in-a-Box) is the future and its happening NOW. The possibilities are endless for encapsulation technology and PMCB has the highest quality encapsulations. The following will lead to the greatest breakthrough in our fight against cancer:
“Radiotherapy and immunotherapy are two key treatments for cancer. There is growing evidence that they are also synergistic, and combination treatments are being studied extensively in the clinical setting. In addition, there is emerging evidence that nanotechnology-enabled therapeutics (Cell-in-a-Box) can potentiate both radiotherapy and immunotherapy, in turn improving both treatments. This is an exciting new area of interdisciplinary science and has significant potential for major clinical impact. Some of the approaches in this area (Cell-in-a-Box) have already reached the clinical stage.”
Great post. I’m not worried at all. 99% of everything amazing we have or know today were enthusiastically doubted. Fortunately for PMCB those days are coming to a close. This is the final stretch and I am very excited.
At $1 I will have $16,400,000. This is the final stretch. Now would be the time to be BOLD.
IND Status Descriptions:
Active (ongoing)
An IND application is in effect and the investigations are ongoing.
On Hold
An active IND application where some or all of the investigations are on clinical hold.
Inactive
An IND application may be inactivated upon the IND applicant’s request or FDA’s request. Inactivation of the IND application may occur if, for example, no subjects entered clinical trial(s) for 2 years or longer, or the IND application is on hold for 1 year or longer. An inactive application may be re-activated if activities under the IND application have restarted.
Withdrawn
An IND application may be withdrawn by the applicant if development of the investigational product has been abandoned for any reason.
Terminated
An IND application may be terminated by FDA if, for example, (1) human subjects are exposed to unreasonable or significant risk, or (2) methods, facilities and controls used for the manufacturing are inadequate to establish and maintain appropriate standards for quality and purity as needed for subject safety.
NICE and exactly
“PharmaCyte's Chief Executive Officer, Kenneth L. Waggoner, said of the completed twelve-month stability study, "We are pleased that our CypCaps(TM) product successfully completed all of the required stability tests and that the product has now shown itself to be stable and active after being stored for 1 year at -80oC. The study will continue in order to determine the maximum shelf life of the CypCaps(TM) product. It should be noted that this data is exceptional for a product of this kind."
“...None of the others can effectively freeze live cells to ship them to anywhere in the world and then be thawed with approximately 95% viability of the encapsulated live cells”
“PharmaCyte’s signature live-cell encapsulation technology, Cell-in-a-Box®, is a one-of-a-kind cell encapsulation technology...”
“In a survey of European biotech/biomedical companies developing advanced therapeutic medicinal products (i.e., products containing living cells like CypCaps(TM)), shelf life issues were reported to be one of the major challenges that such products face (ten Ham et al., 2018, Molecular Therapy: Methods & Clinical Development vol. 11, pp121-130). Laboratory data on non-GMP produced encapsulated cells have suggested that the shelf life of Cell-in-a-Box products stored at -80oC is even longer than 1 year.”
IND Status Descriptions:
Active (ongoing)
•An IND application is in effect and the investigations are ongoing.
On Hold
•An active IND application where some or all of the investigations are on Clinical Hold.
Inactive
•An IND application may be inactivated upon the IND applicant’s request or FDA’s request. Inactivation of the IND application may occur if, for example, no subjects entered clinical trial(s) for 2 years or longer, or the IND application is on hold for 1 year or longer. An inactive application may be re-activated if activities under the IND application have restarted.
Withdrawn
•An IND application may be withdrawn by the applicant if development of the investigational product has been abandoned for any reason.
Terminated
•An IND application may be terminated by FDA if, for example, (1) human subjects are exposed to unreasonable or significant risk, or (2) methods, facilities and controls used for the manufacturing are inadequate to establish and maintain appropriate standards for quality and purity as needed for subject safety. Additional information on the grounds for termination of an IND application may be found in 21 CFR 312.44.
////////////////////////////////
PMCB: END GAME: VALUE
////////////////////////////////
•Company Buyout Evaluation
•W/Success Of Pancreatic Clinical Trial
•CellInABox Primary Function Can Treat
•Multiple Cancers
•Diabetes
•Other Ailments
•Includes A Well Protected 20yr Patent
•Opinion >$10 A Share
////////////////////////////////
PMCB: CELL IN A BOX: TECH
////////////////////////////////
•Smuggles Engineered Cells To Cancer
•Avoids Detection Of Immune System
•Engages w/Chemo Drug At Source
•Mimics Standard Liver Drug Interaction
•Far More Efficiently
•With Less Dilution & More Precision
•One Third of Chemo Drug Needed
•Little To No Side Effects
•Reduced Treatment Time
////////////////////////////////
PMCB: EVERYDAY: IS GREEN
////////////////////////////////
•Current Price Does Not Matter
•There Are Few Insiders Because
•Companies Dont Want PMCB Success
•PMCB Tech Will Hurt Profits
•w/Risk Of Losses & No Privy Info
•Bigs Are Not Secretly Buying
•Its Just Us And Shorts
•Until The Time Is Right And PMCBs
•Technology Can Speak For Itself
////////////////////////////////
PMCB: ANYTHING CAN HAPPEN: 2021
////////////////////////////////
•FDA Approval
•Expedited clinical trial
•Trial success
•Buyout
EVERYDAY IS GREEN FOR PMCB
HOW CAN YOU PUT A PRICE ON THIS TECHNOLOGY? Well YOU CAN and its HUGE >$10 a share HUGE. It DOES NOT matter what the price is right now. Dont expect corporate bigs to be increasing this stock price. My guess is that there is very few insiders secretly investing. Why? Because many of the large companies that are interested in this tech are also wary of it. Only one will gain the rights to PMCBs cellinabox technology. The rest could lose a $$$$ load of money not only because they missed out but also because this tech will impact the different ways these companies profit from the current medical landscape. Both in Oncology and Diabetes. Many dont want PMCB to succeed. If I was PMCB I would not say $$$$ to anyone. To those who invest now. Your gains would multiply exponentially and you wont have to wait long because the FDA will fast track this clinical trial following its approval(2021)
Kenneth Waggoner The Little Engine That Could
I am not worried at all about PMCB. It could go back to .0053 where i bought it and id be fine. Updates should push us up yes. But don’t expect many corporate bigs to be secretly investing.
Many of the same corporations that are interested in this technology are also wary of it. Ultimately only one of them will gain the rights to it through a buyout. A 20 year patent with layers of legal protection. A two decade monopoly...
The rest would lose out and many would take a huge financial hit. PMCBs cell in a box technology and treatment would significantly change the medical landscape.
One example is the companies that supply chemo drugs. With cell in a box.. only 1/3rd the amount of the drug is needed in its treatment and the treatment would be over much faster. Less chemo drugs. Less money. So yes these companies would love to acquire this ground breaking technology but the odds are probably bad considering the competition. Many companies would feel this way. Which means many companies would not want this technology to succeed.
My guess is that there is very few insiders given the situation.
If I were PMCB I would not tell big companies $$$$. Until the time is right and the technology speaks for itself during the clinical trials.
So in my mind. The price is the price. We are waiting on four things. FDA approval. Expedited clinical trial. A successful trial. And a buy out.
I believe PMCB will get FDA approval this year 2021. It could take longer but I do not see that happening. The situation is fluid and based on the last updates. PMCB is hauling $$$. Anything can happen.
“Make it rain” -K Wagy
Mark Meeee Green Skies on the horizon
Kenny Pockets
Wrong. The FDA has the ind.
Over 50% of ind’s get lifted within year1 (Biotech ind’s)
Withdraw is the official word for rejection. I did not read anything about a withdrawal. ind was placed on hold not withdrawn.
“Whats in my pocket” -Uncle Kenny
MARK ME. Kennys got a super special surprise for us tomorrow.
This stock is a machine
Mark Me
Green Machine
MARK ME. Monday Tuesday Wednesday Thursday Friday will be green.
Invest today. Mark Me. Monday. Will be special.
I think its time we have an honest discussion about Kenneth Waggoner.
I have my greatest feeling yet